Program
apremilast
Also written as “Apremilast”, “Apremilast 20mg” and “Apremilast 30mg”.
Its studies are mostly in Psoriasis · Arthritis, Psoriatic · Behcet Syndrome · Arthritis, Juvenile · COVID-19, led by 3 companies.
Drug pageApremilast: every studyAll 117 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Amgenits history only | 464 open or running | phase 4since Apr 3, 2015 | Apr 2, 2007 | Jan 10, 2027phase 1 · NCT07908641 |
| Boehringer Ingelheim | 10 open or running | phase 1since Mar 22, 2021 | Mar 22, 2021 | none ahead |
| Humanis Saglık Anonim Sirketiits history only | 10 open or running | phase 3since Oct 10, 2023 | Oct 10, 2023 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Boehringer Ingelheim only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 22, 2021First study: phase 1 study in HealthyFirst studyNCT04811573 · 20 enrolled · Germany
TargetBeta
“Phosphodiesterase 4 inhibitor”ChEMBL 37, by rule
Other programs on the same 4 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Roflumilastrule | AstraZeneca | phase 4 | 61 |
| ensifentrinerule | Merck | phase 3 | 17 |
| difamilastrule | Otsuka | phase 3 | 16 |
| tanimilastrule | Chiesi Farmaceutici | phase 3 | 15 |
Studies
The one study Boehringer Ingelheim leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04811573Healthy · Germany | 1 | Terminated | Aug 18, 2021 | 20 |
How it is read
Names in the registry
- “Apremilast”, 31 entries
- “Apremilast 20mg”, 6 entries
- “Apremilast 30mg”, 5 entries
- “Apremilast (CC-10004)”, 3 entries
- “Apremilast 30 mg”, 3 entries
Conditions, from the studies’ own filings
- Psoriasis, 18 studies
- Arthritis, Psoriatic, 12 studies
- Behcet Syndrome, 4 studies
- Arthritis, Juvenile, 1 study
- COVID-19, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.